UNSPSC 51192601: Amifostine/mannitol

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class AN700. This VA Drug Class (AN700) classifies this compound as belonging to the group PROTECTIVE AGENTS.

UNSPSC 51192601 Amifostine/mannitol is a Commodity code covering pharmaceutical products and active ingredients procured through state and local cooperative purchasing vehicles and direct government health and corrections agency contracts. State and local governments buy amifostine and mannitol formulations—typically as generic multi-source drugs supplied through authorized wholesaler networks—for use in hospital and correctional-facility pharmacies, emergency medical services, and public health clinics. The issuing bodies are primarily state health departments, correctional agencies, and multistate cooperative purchasing alliances that pool demand across participating jurisdictions to achieve volume pricing and supply consistency. Recent activity shows state and local procurement offices working through established pharmaceutical supply agreements with cGMP-certified manufacturers and licensed wholesalers, emphasizing compliance with the Drug Supply Chain Security Act, FDA registration, and shelf-life guarantees of at least one year from manufacture.

The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued an RFP on January 20, 2026 (due March 26, 2026) to establish multiple contracts for generic multi-source pharmaceuticals and OTC products distributed across participating state and local government facilities, including Oregon. The RFP requires vendors to supply products through three authorized wholesalers—AmerisourceBergen Drug Corporation (Cencora), Cardinal Health 110 and 112, and Morris & Dickson Co., LLC—and mandates detailed product documentation including National Drug Codes, SKUs, UPCs, strength, dosage form, and manufacturing locations. Evaluation weights 75 percent on price competitiveness, 10 percent on fixed pricing for the contract term, and 5 percent each on administrative fee data format compliance, EDI capability, and agreement to a 3 percent administrative fee. The contract term runs two years for new vendors with optional extensions, while incumbent amendments align through June 30, 2028, with awards effective July 1, 2026.